Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe
SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational antiepileptic drug for the potential treatment of partial-onset seizures in adult patients. Under the agreement, SK Biopharmaceuticals will receive an upfront payment of $100 million and is eligible to receive up to $430 million upon achievement of certain regulatory and commercial milestones in addition to royalties on net sales generated in Europe. SK Biopharmaceuticals will have an option to obtain a significant equity stake in Arvelle and will also retain commercial rights for all non-European territories. Cenobamate was discovered and developed by SK Biopharmaceuticals from inception through to the acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA).
“We are very pleased to enter into this licensing agreement with Arvelle, as it provides important validation of the global potential for cenobamate as a new treatment option for adults with partial-onset seizures,” said Dr. Jeong Woo Cho, President and CEO of SK Biopharmaceuticals. “Arvelle’s experienced leadership team and focus on CNS disorders make them the ideal partner to advance the development and commercialization of our compound in Europe.”
Arvelle Therapeutics is a newly created company that received one of the largest initial financing commitments for a European-focused biopharmaceutical company from a global syndicate of investors that include NovaQuest, LSP, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners. Mark Altmeyer has been named President and CEO of Arvelle. Altmeyer brings more than 30 years of global biopharmaceutical experience to Arvelle. As President and CEO of Otsuka America Pharmaceutical, Inc., Altmeyer oversaw the growth of Abilify® into a multi-billion-dollar product. Most recently, he served as President and Chief Commercial Officer of Axovant Sciences and previously led the neuroscience business unit at Bristol-Myers Squibb Company. Altmeyer is joined by a talented team of colleagues from Axovant with deep experience in CNS drug development and global commercialization. Arvelle intends to file a Marketing Authorization Application (MAA) for cenobamate for partial-onset seizures in adult patients based on the data generated from SK Biopharmaceuticals’ global clinical trial program.
“We launched Arvelle to bring truly innovative CNS products to patients suffering from serious neurological conditions and cenobamate is the perfect first pipeline product,” said Altmeyer. “Given the data generated in clinical trials and the FDA acceptance of the NDA, we believe cenobamate has the potential to be an important antiepileptic drug treatment option for adult patients suffering from partial-onset seizures. We appreciate the support and validation of our investors and are very enthusiastic about our potential in the European market.”
“We are very excited to invest in the talented team at Arvelle on this new venture,” said Martijn Kleijwegt, Managing Partner of LSP. “SK Biopharmaceuticals has done an excellent job on the discovery and development of cenobamate and we believe that Arvelle is the right company to gain EU approval for cenobamate and ultimately bring it to patients in Europe.”
About Cenobamate
Cenobamate (YKP3089) was discovered by SK Biopharmaceuticals and SK life science and is being investigated for the potential treatment of partial-onset seizures (also known as “focal seizures”) in adult patients. Cenobamate’s mechanism of action is not fully understood, but it is believed to work through two separate mechanisms: enhancing inhibitory currents through positive modulation of GABA-A receptors and decreasing excitatory currents by inhibiting the persistent sodium current.
Global trials for adults with partial-onset seizures are ongoing to evaluate cenobamate safety. An additional clinical trial is investigating cenobamate safety and efficacy for another form of epilepsy in adult patients.
The U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application for cenobamate for the potential treatment of partial-onset seizures in adults in February 2019.
Cenobamate is not approved by the FDA, European Medicines Agency (EMA) or any other regulatory authorities. Safety and efficacy have not been established.
About SK Biopharmaceuticals
SK Biopharmaceuticals is focused on research and development of treatments for disorders of central nervous system (CNS) and cancer. SK Biopharmaceuticals is an affiliate of SK Group, the second largest conglomerate in Korea.
Currently, SK Biopharmaceuticals is conducting basic research for the development of innovative new drugs at its research center in Pangyo, Gyeonggi Province, Korea. Further, the company is pursuing global clinical development and direct marketing through its U.S. subsidiary SK Life Science, Inc., in Fair Lawn, New Jersey, USA.
SK Biopharmaceuticals has a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize, cenobamate (YKP3089), is an investigational compound for the potential treatment of partial-onset seizures in adult patients. The NDA for cenobamate for the potential treatment of partial-onset seizures in adult patients is currently under review by the FDA. For more information, visit SK Biopharmaceuticals’ website at www.skbp.com/eng.
About Arvelle Therapeutics
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. More information is available at http://arvelletx.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005290/en/
Contact information
For Arvelle Therapeutics:
Mike Beyer, Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirion to Join the U.S. Industry Program at the 69th IAEA General Conference in Vienna, Austria11.9.2025 23:39:00 EEST | Press release
Mirion, a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, is honored to announce its invitation to attend the 69th International Atomic Energy Agency (IAEA) General Conference. Scheduled for September 15–19 in Vienna, Austria, this annual event brings together key stakeholders from across the globe to discuss issues critical to nuclear safety, security, and peaceful applications of nuclear technology. Representing Mirion at the General Conference will be Chairman and Chief Executive Officer Thomas Logan and Chief Financial Officer Brian Schopfer. Their presence underscores the distinguished role Mirion plays as an industry leader in nuclear measurement, radiation protection, and safety solutions, in addition to its commitment to innovation and advancing global energy solutions. “We are honored to participate in this important global gathering,” Logan said. “The IAEA plays a crucial role
René Lammers Appointed Chief Research & Innovation Officer of The Estée Lauder Companies11.9.2025 23:25:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of René Lammers, Ph.D. as Executive Vice President, Chief Research & Innovation Officer, effective October 1, 2025. Mr. Lammers will report directly to Stéphane de La Faverie, President and Chief Executive Officer, and will join the company’s Executive Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911004836/en/ René Lammers, Ph.D., Executive Vice President, Chief Research & Innovation Officer “René is an exceptional and innovative leader whose deep scientific expertise, global perspective, and passion for cutting-edge product development will be instrumental as we transform our approach to research and innovation to more fully align with our focus on consumer centricity,” said Mr. de La Faverie. “Creating transformative innovation is integral to our strategic vision of Beauty Reimagined, and with René’s leadership, we are elevating our capab
RTL Luxembourg Expands Deployment of Verimatrix Technologies to Protect Premier Auto Racing Against Piracy11.9.2025 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that RTL Luxembourg, the country’s leading media company, has further expanded its use of Verimatrix anti-piracy tools to now include the full Streamkeeper suite of solutions. Initially deploying Streamkeeper Multi-DRM, RTL Luxembourg also recently implemented Counterspy, Deepscan and Watermarking solutions – the industry’s latest set of powerful tools that help further bolster proactive protections for RTL’s motorsport content revenue. It was announced in April 2024 that RTL Luxembourg selected Verimatrix Streamkeeper Multi-DRM to ensure that RTL Luxembourg remained in full control of its valuable digital assets while also consistently keeping costs low and preventing unneeded technical complexities. With the addition of Verimatrix’s Counterspy, RTL Luxembourg further expands its ability to detect unauthorized content distribution in real-time, depl
Xylem and Amazon Partner on Smart Water Upgrades to Save More Than 1.3 Billion Liters Annually in Mexico11.9.2025 17:00:00 EEST | Press release
Residents in Mexico City and Monterrey will soon enjoy more reliable water supply as the two cities launch groundbreaking infrastructure upgrades to save over 1.3 billion liters of water a year – easing pressure from the rapid urbanization and persistent drought conditions that have strained local water systems. The two cities are working in partnership with global water technology company Xylem (NYSE: XYL) and Amazon (NASDAQ: AMZN) to deploy Xylem Vue, an advanced software platform that applies data and analytics to detect leaks, cut water losses and improve residents’ water supply. The projects are estimated to save upwards of 800 million liters of water a year in Mexico City and 560 million liters a year in Monterrey. “In a water-stressed region, where every liter counts, recovering more than a billion liters of water each year is a game-changer,” said Jaime Barba, General Manager, Xylem Vue. “Working with Amazon and the local water utilities, we are using data to give these cities
HTEC Partners with World Economic Forum11.9.2025 16:56:00 EEST | Press release
HTEC, a global digital engineering and product development company, has today announced that it has joined the World Economic Forum’s (WEF) Centre for AI Excellence. HTEC will contribute to the community through its expertise and thought leadership to help advance AI adoption and AI innovation across its core industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911910448/en/ HTEC Partners with World Economic Forum to bring AI expertise to help with industry transformation and real-world outcomes WEF’s Centre for AI Excellence is bringing together leading industry organisations and experts to work together to advance the pace and positive impact AI can have in economies and societies. Its goal is to unlock transformative potential in an equitable and human-centered way, which is well aligned with HTEC’s principles and values. As an AI-first organization, HTEC blends deep engineering expertise with strategic insight.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom